Therapy of thyroid cancer. Recombinant TSH
Nuklearmedizin. Nuclear Medicine 41(1): N9-10
2002
ISSN/ISBN: 0029-5566 PMID: 11917353 Document Number: 544772
Document emailed within 1 workday
Related Documents
Fu, H.; Ma, C.; Tang, L.; Wu, F.; Liu, B.; Wang, H. 2015: Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 59(1): 121-128Jurincic-Winkler, C.; Horlbeck, R.; Klippel, K.F. 1993: Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer Wiener Klinische Wochenschrift 105(10): 271-276
Gorman, C.A.; Becker, D.V.; Greenspan, F.S.; Levy, R.P.; Oppenheimer, J.H.; Rivlin, R.S.; Robbins, J.; VanderLaan, W.P. 1977: American thyroid association statement: breast cancer and thyroid hormone therapy Annals of Internal Medicine 86(4): 502-503
Testori, O.; Bagnasco, M.; Banti, E.; Bombardieri, E.; Dottorini, M.E.; Fugazzola, L.; Maffioli, L.; Perotti, G.; Rubello, D.; Seregni, E. 2012: Radiometabolic therapy for metastatic thyroid carcinoma: overview of the literature and rational bases for the use of recombinant human TSH Minerva Medica 103(3): 209-218
Hasse-Lazar, K.; Handkiewicz-Junak, D.; Roskosz, Józef.; Szpak-Ulczok, S.; Krajewska, J.; Jurecka-Lubieniecka, B.; Jarzab, B. 2006: Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences Endokrynologia Polska 57(4): 445-450
Liu, B.; Kuang, A. 2012: Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 29(3): 588-592
Nozaki, H.; Funahashi, H.; Sato, Y.; Imai, T.; Oike, E.; Kato, M.; Takagi, H. 1991: Study of hormone replacement therapy following total thyroidectomy in thyroid cancer--with special reference to the analysis of thyroid hormone peripheral effects, using indirect calorimetry Nihon Geka Gakkai Zasshi 92(12): 1700-1707
Cochet, O.; Gruel, N.; Fridman, W.H.; Teillaud, J.L. 1999: Ras and p53 intracellular targeting with recombinant single-chain Fv (scFv) fragments: a novel approach for cancer therapy? Cancer Detection and Prevention 23(6): 506-510
Campioni, N. 1970: Therapy of cancer of the thyroid gland Il Policlinico. Sezione Pratica 77(31): 997-1005
Beguin, Y. 2002: Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients Haematologica 87(11): 1209-1221
Böttger, T.; Klupp, J.; Sorger, K.; Junginger, T. 1991: Therapy and prognosis of medullary thyroid cancer Medizinische Klinik 86(1): 8-14
Horácek, Jí. 2015: Radioiodine therapy in patients with low-thyroid cancer Vnitrni Lekarstvi 61(9): 755-757
Reiners, C.; Farahati, J. 1999: 131i therapy of thyroid cancer patients Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 43(4): 324-335
Einhorn, J. 1977: Radiation therapy of differentiated thyroid cancer Lakartidningen 74(35): 2893-2896
Dietlein, M.; Dressler, J.; Farahati, J.; Leisner, B.; Moser, E.; Reiners, C.; Schicha, H.; Schober, O. 1999: Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer Nuklearmedizin. Nuclear Medicine 38(6a): 221-222
Rozdil'skiĭ, S.I.; Afanas'eva, N.I.; Nachinova, N.A.; Tkachenko, G.I.; Astap'eva, O.N.; Vasil'ev, L.I.; Duma, V.A. 1992: The characteristics of the clinical course and therapy of thyroid cancer in children Terapevticheskii Arkhiv 64(10): 55-58
McMannis, J.D.; Fisher, R.I.; Creekmore, S.P.; Braun, D.P.; Harris, J.E.; Ellis, T.M. 1988: In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2 Journal of Immunology 140(4): 1335-1340
Shimizu, K.; Mimura, T.; Harada, T.; Tanaka, S. 1994: Current status and prospects for targeted therapy for thyroid cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 743-748
Li, Z.; Shanmugam, N.; Katayose, D.; Huber, B.; Srivastava, S.; Cowan, K.; Seth, P. 1997: Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase Cancer Gene Therapy 4(2): 113-117
Goretzki, P.E.; Frilling, A.; Ohmann, C.; Wins, L.; Grussendorf, M.; Röher, H.D. 1989: Various strategies in the diagnosis and therapy of thyroid gland cancer. Results of a survey Der Chirurg; Zeitschrift für Alle Gebiete der Operativen Medizen 60(6): 398-402